- Home
- MCR vs CATX Comparison
MCR vs CATX Comparison
Compare MCR & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCR | CATX |
|---|---|---|
| Founded | 1989 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.3M | 569.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | MCR | CATX |
|---|---|---|
| Price | $6.06 | $4.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 92.4K | ★ 1.4M |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.71 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.57 | $1.60 |
| 52 Week High | $6.57 | $6.16 |
Technical Indicators
Market Signals| Indicator | MCR | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 25.86 | 48.36 |
| Support Level | $6.00 | $4.77 |
| Resistance Level | $6.36 | $5.96 |
| Average True Range (ATR) | 0.06 | 0.36 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 16.67 | 12.95 |
Price Performance
Historical ComparisonAbout MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.